Dactylitis

Global Psoriatic Arthritis Treatment Market Report 2023: Recent Development of Interleukin-17 Inhibitors Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 18, 2023
Health, Other Health, Secukinumab, Psoriatic arthritis, Arthritis mutilans, Arthritis, Spondylitis, Public, Tendinopathy, Arthritis Foundation, Psoriasis, Woman, Brodalumab, UCB, Dactylitis, Patient, Celgene, Certolizumab pegol, Ixekizumab, Diagnosis, Skin, Disease, Pharmaceutical industry

It is a heterogeneous disease and is categorized into 5 subtypes, namely, symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans.

Key Points: 
  • It is a heterogeneous disease and is categorized into 5 subtypes, namely, symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans.
  • The factors driving the psoriatic arthritis treatment market are rising public health awareness regarding skin diseases, early disease diagnosis, and the recent development of interleukin-17 inhibitors.
  • Currently, the drugs prescribed for psoriatic arthritis are based on the severity of the disease such as mild, moderate, or severe psoriatic arthritis.
  • The development of Interleukin-17 inhibitors such as secukinumab, ixekizumab, and brodalumab have better drug safety and efficacy for the treatment of psoriatic arthritis.

Long-Term Psoriatic Arthritis Data for AbbVie's Skyrizi Likely to Impact Future IL-23 Preference, Spherix Global Insights Reports

Retrieved on: 
Wednesday, December 21, 2022
Patient, Gastroenterology, HCP, Dermatology, Nephrology, ACR20, Rheumatology, Novartis, JAK, Janssen, Neck, Dactylitis, News, Psoriatic arthritis, Keepsake, IL-23, AbbVie, TNF, PASI, Ophthalmology, Skin, Neurology, Pharmaceutical industry, Guselkumab, Risankizumab, Upadacitinib

EXTON, Pa., Dec. 21, 2022 /PRNewswire/ -- Spherix Global Insights, a leading provider of market research, business intelligence, and advisory services to the global life sciences industry, has been tracking the evolution of the US psoriatic arthritis (PsA) market for seven years, including the uptake and impact of various market entrants.

Key Points: 
  • RealTime Dynamix™ is an independent study service by Spherix Global Insights that provides strategic guidance through quarterly or semiannual reports.
  • Spherix Global Insights is a leading provider of market research, business intelligence and advisory services to the global life sciences industry.
  • A trusted advisor and industry thought leader, Spherix Global Insights provides specialized market expertise in six (6) focused therapeutic areas including: dermatology, gastroenterology, nephrology, neurology, rheumatology and ophthalmology.
  • To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn and Twitter .

U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis

Retrieved on: 
Friday, January 21, 2022
Patient, Research, Inflammation, ACR20, Psoriatic arthritis, TB, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease-modifying antirheumatic drug, Risankizumab, Allergy, NYSE, AbbVie, Safety, Adult, Achievement, Psoriasis Area and Severity Index, Joint, DMARD, Boehringer Ingelheim, Keepsake, Swelling, History, Psoriasis, Fatigue, Skin, Pain, Arthralgia, Infection, Crohn's disease, Rheumatology, Dactylitis, Diagnosis, PASI, Health assessment, Dermatology, Food, Risk, Immune system, ABBV, Light, FDA, Interleukin, Tuberculosis, Pharmaceutical industry, Dietary supplement, Medical imaging, Palladium, Health insurance, CPI

"We're proud to expand the use of SKYRIZI to patients with psoriatic arthritis who are living with the debilitating combination of skin and joint symptoms."

Key Points: 
  • "We're proud to expand the use of SKYRIZI to patients with psoriatic arthritis who are living with the debilitating combination of skin and joint symptoms."
  • SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization of SKYRIZI globally.
  • The overall safety profile observed in patients with psoriatic arthritis treated with SKYRIZI is generally consistent with the safety profile in patients with plaque psoriasis.
  • Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

DGAP-News: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)

Retrieved on: 
Wednesday, December 2, 2020
Medical specialties, Clinical medicine, Rheumatology, Medicine, Autoimmune diseases, Psoriasis, Monoclonal antibodies, MorphoSys, Psoriatic arthritis, Guselkumab, Dactylitis, Enthesitis, the DISCOVER program, MorphoSys

PLANEGG/MUNICH, Germany, December 2, 2020-MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC.

Key Points: 
  • PLANEGG/MUNICH, Germany, December 2, 2020-MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC.
  • "As a new, first-in-its-class treatment option for patients with psoriatic arthritis, Tremfya provides much-needed treatment opportunities to improve the lives of patients suffering from this debilitating disease", said Dr. Malte Peters, Chief Research and Development Officer at MorphoSys.
  • "We are very pleased and extremely proud that Tremfya has been approved by the European Commission for the treatment of adult patients with active psoriatic arthritis in the European Union."
  • It is characterized by debilitating joint damage, inflammation, enthesitis, dactylitis, axial disease, and skin lesions generally associated with psoriasis.